Semaglutide is not currently approved for the treatment of type 1 diabetes, and its safety and efficacy in this population have not been established
Managing postpartum weight gain: 3 lifestyle interventions Stopping semaglutide can lead to weight regain, which might carry over into postpartum
Evernorth's pharmacy benefit services business generated $609 million in adjusted pretax earnings, reflecting the financial impact of previously announced client contract renewals and investments in the company's new rebate-free pharmacy benefit model, known as "Signature." The company is seeing strong early interest from health plans and employers as it prepares for a broader commercial rollout of Signature in 2028, Evanko said
If gastrointestinal side effects prevent escalation at a scheduled step, the current dose should be maintained for an additional four weeks before attempting to increase
Its crucial to disclose all relevant information during your consultation to ensure your safety
It is also looking at acquiring a fast-track review by the Federal Drug Administration